Human FXYD5 ELISA Kit (V2LY-0626-LY4599)

Hotta, T., Nariai, Y., Kajitani, N., Kadota, K., Maruyama, R., Tajima, Y., ... & Urano, T. (2023). Generation of the novel anti-FXYD5 monoclonal antibody and its application to the diagnosis of pancreatic and lung cancer. Biochimie.

Tan, X. P., Xiong, B. H., Zhang, Y. X., Wang, S. L., Zuo, Q., & Li, J. (2022). FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma. European Journal of Pharmacology, 931, 175186.

Song, L., Li, X., Sun, Q., & Zhao, Y. (2022). Fxyd5 activates the NF‑κB pathway and is involved in chondrocytes inflammation and extracellular matrix degradation. Molecular Medicine Reports, 25(4), 1-8.

Ding, L., & Li, J. (2022). FXYD domain containing ion transport regulator 5 (FXYD5) silencing promotes cell viability and alleviates inflammatory response in cerulein-induced AR42J cells by blocking JAK2/STAT3 signaling pathway. Bioengineered, 13(2), 2639-2647.

Juurikka, K., Dufour, A., Pehkonen, K., Mainoli, B., Campioni Rodrigues, P., Solis, N., ... & Åström, P. (2021). MMP8 increases tongue carcinoma cell–cell adhesion and diminishes migration via cleavage of anti-adhesive FXYD5. Oncogenesis, 10(5), 44.

Jan, V., Miš, K., Nikolic, N., Dolinar, K., Petrič, M., Bone, A., ... & Pirkmajer, S. (2021). Effect of differentiation, de novo innervation, and electrical pulse stimulation on mRNA and protein expression of Na+, K+-ATPase, FXYD1, and FXYD5 in cultured human skeletal muscle cells. Plos one, 16(2), e0247377.

Liu, Y. K., Jia, Y. J., Liu, S. H., Shi, H. J., & Ma, J. (2021). Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells. Histology and Histopathology, 36(5), 535-545.

Bai, Y., Li, L. D., Li, J., Chen, R. F., Yu, H. L., Sun, H. F., ... & Lu, X. (2020). A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer. International Journal of Oncology, 56(1), 301-314.

Tassi, R. A., Gambino, A., Ardighieri, L., Bignotti, E., Todeschini, P., Romani, C., ... & Ravaggi, A. (2019). FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. British Journal of Cancer, 121(7), 584-592.

Besso, M. J., Rosso, M., Lapyckyj, L., Moiola, C. P., Matos, M. L., Mercogliano, M. F., ... & Vazquez-Levin, M. H. (2019). FXYD5/Dysadherin, a biomarker of endometrial cancer myometrial invasion and aggressiveness: its relationship with TGF-β1 and NF-κB pathways. Frontiers in Oncology, 9, 1306.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols